Balanced news tone
News Sentiment
BHC sentiment intelligence
Bausch Health Companies Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
52
Balanced news tone
55 relevant articles
News tone and price action are not far from neutral.
79/100 classification confidence.
directly relevant articles
high-authority source matches
-2.4% over one week, -5.5% over four weeks, trend inactive, and below fair value.
BHC4634780 Bond Profile — Key Metrics
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
79/100 classification
One-week reaction
-2.4%
Price reacting lower
Trend fit
Trend inactive
-5.5% over four weeks
Fair value
-31.5%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
7
Neutral
46
Negative
2
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
TradingView
Direct company coverage
BHC4634780 Bond Profile — Key Metrics
This article provides a detailed profile of the Bausch Health Companies Inc. 8.5% bond, maturing on January 31, 2027, under the identifier BHC4634780. It outlines key bond metrics such as the issue and maturity dates, outstanding amount, face value, and coupon rate, alongside a d
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 23:09
- Source
- TradingView
Insider Monkey
Direct company coverage
Bausch Health’s (BHC) Canadian Subsidiary Lists PrOKEDI Dosages in RAMQ Formulary
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jul 2026 17:21
- Source
- Insider Monkey
ad-hoc-news.de
Direct company coverage
Bausch Health stock reflects a complex turnaround story for investors
Bausch Health Companies Inc. (BHC) is currently undergoing a multi-year turnaround, focusing on restructuring, debt reduction, and strategic repositioning of its diversified healthcare businesses. The company, known for branded pharmaceuticals and eye-care products, faces the cha
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 12 Jul 2026 05:10
- Source
- ad-hoc-news.de
Investing.com
Direct company coverage
Bausch + Lomb launches AI-powered digital health platform
Bausch + Lomb has introduced Orphia, an AI-powered digital health platform within its new Digital Health Services division. Developed with Hippocratic AI, Orphia aims to reduce administrative burdens for eye care providers, starting with pre-surgery cataract education. The platfo
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 12:40
- Source
- Investing.com
AD HOC NEWS
Direct company coverage
Bausch Health Companies updates its path in pharmaceuticals as investors watch broader sector trends
Bausch Health Companies is continuing its turnaround strategy by focusing on branded pharmaceuticals and eye care, streamlining operations, and reducing its debt. The company emphasizes high-margin products in eye health, dermatology, and gastrointestinal treatments, while also w
- Tone
- Positive 67/100
- Event
- Balance sheet
- Published
- 09 Jul 2026 00:39
- Source
- AD HOC NEWS
Moomoo
Direct company coverage
Bausch Health to Announce Second Quarter 2026 Results on July 29, 2026
Bausch Health Companies Inc. is scheduled to announce its second quarter 2026 financial results on July 29, 2026. The company will also host a conference call and webcast to discuss these results, providing an opportunity for investors and analysts to gain insights into its perfo
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 08 Jul 2026 00:39
- Source
- Moomoo
Baystreet.ca
Direct company coverage
Bausch Health Companies Inc.
Bausch Health Companies Inc. shares were trading up $0.07 at $6.90. The company is scheduled to release its second-quarter 2026 financial results after market close on Wednesday, July 29.
- Tone
- Positive 60/100
- Event
- Earnings
- Published
- 07 Jul 2026 14:12
- Source
- Baystreet.ca
24/7 Wall St.
Direct company coverage
BHC Stock Price Prediction 2025-2026 | Bausch Health Companies Inc Forecast
24/7 Wall St. has issued a "BUY" rating for Bausch Health Companies Inc (BHC), projecting a target price of $6.81 within the next 12 months, representing a 38.73% upside from its current price of $4.91. The forecast includes an optimistic scenario of $7.63 and a conservative scen
- Tone
- Positive 72/100
- Event
- Analyst action
- Published
- 07 Jul 2026 13:10
- Source
- 24/7 Wall St.
Stock Titan
Direct company coverage
Bausch Health plans July 29 call for Q2 results and business update
Bausch Health (NYSE: BHC) is scheduled to release its second-quarter 2026 financial results after market close on Wednesday, July 29, 2026. The company will also host a live conference call and webcast at 5:00 p.m. U.S. EDT to discuss the results and provide a business update, wi
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 Jul 2026 11:09
- Source
- Stock Titan
Yahoo! Finance Canada
Direct company coverage
Québec is the first province to list (Pr)OKEDI(MC) (extended-release injectable suspension of risperidone) on the public drug reimbursement formulary for the treatment of schizophrenia
Québec has become the first province to list PrOKEDI® (extended-release injectable suspension of risperidone) on its public drug reimbursement formulary for the treatment of schizophrenia in adults, effective June 25th, 2026. This decision, announced by Bausch Health, Canada Inc.
- Tone
- Positive 70/100
- Event
- Market update
- Published
- 06 Jul 2026 10:59
- Source
- Yahoo! Finance Canada
Stock Titan
Direct company coverage
Bausch Health (BHC) director granted RSUs in lieu of cash fees
Bausch Health Companies Inc. director Amy B. Wechsler received 1,394 Restricted Share Units (RSUs) valued at $4.93 per share, instead of cash compensation for her board service for the quarter ending June 30, 2026. This transaction increased her direct holdings to 314,979 common
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 02 Jul 2026 20:09
- Source
- Stock Titan
Stock Titan
Direct company coverage
Bausch Health (NYSE: BHC) director granted 6,845 RSUs as board compensation
Bausch Health Companies Inc. director Sandra Leung was granted 6,845 Restricted Share Units (RSUs) as compensation for her board service, valued at $4.93 per share, for the quarter ending June 30, 2026. This RSU grant is a routine, compensation-related award and not an open-marke
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 02 Jul 2026 20:09
- Source
- Stock Titan
Stock Titan
Direct company coverage
Bausch Health (NYSE: BHC) director John Paulson granted 12,677 RSUs as board pay
Bausch Health Companies Inc. director John Paulson was granted 12,677 Restricted Share Units (RSUs) as compensation for his board service for the quarter ending June 30, 2026. Each RSU is valued at $4.93 per share and represents a contingent right to receive one common share. Fol
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 02 Jul 2026 20:09
- Source
- Stock Titan
www.marketscreener.com
Direct company coverage
Bausch Health Companies Inc. Announces Resignation of Michael Goettler from Director Role, Effective June 30, 2026
Bausch Health Companies Inc. announced that Michael Goettler has resigned from its Board of Directors, effective June 30, 2026. This resignation is due to his appointment as President and Chief Executive Officer of Knoa Pharma LLC. The company clarified that his departure was not
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 10:12
- Source
- www.marketscreener.com
PR Newswire
Direct company coverage
Michael Goettler Resigns from Bausch Health's Board of Directors
Michael Goettler has resigned from the Board of Directors of Bausch Health Companies Inc., effective June 30, 2026. This resignation is due to his new appointment as President and Chief Executive Officer of Knoa Pharma LLC. Bausch Health expressed gratitude for his service, notin
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 20:40
- Source
- PR Newswire
Stock Titan
Direct company coverage
Bausch Health board loses Goettler as he takes Knoa Pharma CEO role
Bausch Health (NYSE:BHC) announced that director Michael Goettler resigned from its Board of Directors, effective June 30, 2026. This resignation follows his appointment as President and Chief Executive Officer of Knoa Pharma LLC. Bausch Health clarified that his departure was no
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 20:40
- Source
- Stock Titan
Stock Titan
Direct company coverage
Director Michael Goettler exits Bausch Health (NYSE: BHC) board
Bausch Health Companies Inc. announced that director Michael Goettler has resigned from its Board of Directors, effective June 30, 2026. This resignation is due to his appointment as President and Chief Executive Officer of Knoa Pharma LLC and was not related to any disagreements
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 20:40
- Source
- Stock Titan
Investing.com Canada
Direct company coverage
Bausch + Lomb survey finds dry eye affects emotional health By Investing.com
Bausch + Lomb's third annual State of Dry Eye survey reveals that dry eye symptoms significantly impact patients' emotional health and well-being, not just physical comfort. The survey found that a substantial percentage of sufferers experienced reduced self-confidence, emotional
- Tone
- Positive 64/100
- Event
- Market update
- Published
- 01 Jul 2026 11:40
- Source
- Investing.com Canada
TradingView
Direct company coverage
Bausch Health Companies Inc. Actuals & Estimates (MUN:BVF)
This article provides an overview of Bausch Health Companies Inc. (BVF) on the Munich Stock Exchange, detailing its financial actuals and analyst estimates. It covers historical stock performance, future price forecasts, earnings, revenue, net income, employee count, and EBITDA.
- Tone
- Positive 60/100
- Event
- Earnings
- Published
- 27 Jun 2026 05:09
- Source
- TradingView
TradingView
Direct company coverage
BVF Forecast — Price Target — Prediction for 2027
The article provides a forecast for Bausch Health Companies Inc. (BVF) stock, including analyst price targets, future earnings, and revenue estimates. It highlights that analysts have a max estimate of 7.91 EUR and a min estimate of 5.90 EUR for BVF's price. The company's last re
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 18:11
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Bausch Health Companies Inc. – FWB:BVF
This article focuses on the "Price to earnings forward" financial metric for Bausch Health Companies Inc., specifically its listing on the Frankfurt Stock Exchange (FWB:BVF). It appears to be a financial data snippet from TradingView, indicating no current trades and a closed mar
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 12:10
- Source
- TradingView
TradingView
Direct company coverage
Bausch Health Companies Inc. Actuals & Estimates (NYSE:BHC)
This article provides an overview of Bausch Health Companies Inc. (NYSE:BHC) financial actuals and estimates, including its current stock price, market capitalization, and volatility. It details analyst forecasts for BHC's future price, past stock performance, and upcoming earnin
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 26 Jun 2026 06:10
- Source
- TradingView
TradingView
Direct company coverage
Bausch Health Companies Inc. Actuals & Estimates (BOATS:BHC)
This article provides an overview of Bausch Health Companies Inc. (BHC) financials, including actuals and analyst estimates for its income statement, balance sheet, and cash flow. It details past earnings and revenue figures, upcoming earnings dates, and analyst price targets, no
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 00:10
- Source
- TradingView
TradingView
Direct company coverage
Bausch Health Companies Inc. Actuals & Estimates (LSX:A2JQ1X)
This article provides an overview of Bausch Health Companies Inc. (A2JQ1X) stock performance, financial actuals, and analyst estimates. It includes current stock price, historical highs and lows, market capitalization, volatility, and details on recent earnings and revenue. The c
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 00:09
- Source
- TradingView
Investing.com
Direct company coverage
Bausch Health stock hits 52-week low at 4.91 USD
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 07:00
- Source
- Investing.com
The Wall Street Journal
Direct company coverage
Health Care Roundup: Market Talk
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 21:06
- Source
- The Wall Street Journal
CNW Group
Direct company coverage
Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance sign letter of intent for public drug plan coverage of (Pr)OKEDI® (Risperidone for extended-release injectable suspension) for the treatment of schizophrenia
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 12:00
- Source
- CNW Group
Seeking Alpha
Direct company coverage
Bausch Health: Invest In The Short-Term Bonds, Not The Stock (NYSE:BHC)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 07:00
- Source
- Seeking Alpha
Market source
Direct company coverage
Bausch (BHC) Down 5.4% Since Last Earnings Report: Can It Rebound?
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 May 2026 07:00
- Source
- Market source
MT Newswires
Direct company coverage
Bausch Health, Solta Medical Say Thermage Brand Receives China Trademark Certification
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 May 2026 20:47
- Source
- MT Newswires